FXYD5

Summary

FXYD5 (FXYD domain containing ion transport regulator 5, HGNC:4029) is a protein-coding gene on chromosome 19q13.12, encoding FXYD domain-containing ion transport regulator 5 (Q96DB9). Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane.

This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, is a glycoprotein that functions in the up-regulation of chemokine production, and it is involved in the reduction of cell adhesion via its ability to down-regulate E-cadherin. It also promotes metastasis, and has been linked to a variety of cancers. Alternative splicing results in multiple transcript variants. [RefSeq curation by Kathleen J. Sweadner, Ph.D., [email protected]., Sep 2009]

Source: NCBI Gene 53827 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 52 total
• MANE Select transcript: NM_014164

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4029
Approved symbol	FXYD5
Name	FXYD domain containing ion transport regulator 5
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	OIT2
Ensembl gene	ENSG00000089327
Ensembl biotype	protein_coding
OMIM	606669
Entrez	53827

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 37 protein_coding, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000342879, ENST00000392217, ENST00000392218, ENST00000392219, ENST00000423817, ENST00000496493, ENST00000541435, ENST00000543307, ENST00000586925, ENST00000588699, ENST00000590686, ENST00000591716, ENST00000592290, ENST00000718431, ENST00000876479, ENST00000876480, ENST00000876481, ENST00000876482, ENST00000876483, ENST00000876484, ENST00000876485, ENST00000922558, ENST00000922559, ENST00000922560, ENST00000922561, ENST00000922562, ENST00000922563, ENST00000922564, ENST00000922565, ENST00000922566, ENST00000922567, ENST00000922568, ENST00000922569, ENST00000922570, ENST00000922571, ENST00000922572, ENST00000922573, ENST00000922574, ENST00000922575, ENST00000922576, ENST00000922577

RefSeq mRNA: 5 — MANE Select: NM_014164 NM_001164605, NM_001320912, NM_001320913, NM_014164, NM_144779

CCDS: CCDS12447, CCDS82328

Canonical transcript exons

ENST00000392219 — 9 exons

Exon	Start	End
ENSE00002740456	35155551	35155611
ENSE00003530382	35158344	35158400
ENSE00003546265	35160709	35160801
ENSE00003552113	35157421	35157501
ENSE00003553308	35166142	35166171
ENSE00003574340	35166251	35166325
ENSE00003622246	35164156	35164245
ENSE00004035068	35169566	35169881
ENSE00004035070	35154735	35154809

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 99.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 404.1695 / max 6806.4813, expressed in 1814 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175237	391.7078	1814
175240	7.2216	1154
175242	1.5129	800
175238	1.3806	693
175241	1.2701	479
175244	0.7327	412
175239	0.3438	188

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.49	gold quality
leukocyte	CL:0000738	98.98	gold quality
monocyte	CL:0000576	98.95	gold quality
mononuclear cell	CL:0000842	98.94	gold quality
stromal cell of endometrium	CL:0002255	98.82	gold quality
ectocervix	UBERON:0012249	98.59	gold quality
spleen	UBERON:0002106	98.54	gold quality
right lung	UBERON:0002167	98.48	gold quality
omental fat pad	UBERON:0010414	98.41	gold quality
ascending aorta	UBERON:0001496	98.38	gold quality
descending thoracic aorta	UBERON:0002345	98.38	gold quality
thoracic aorta	UBERON:0001515	98.37	gold quality
endocervix	UBERON:0000458	98.36	gold quality
peritoneum	UBERON:0002358	98.35	gold quality
right coronary artery	UBERON:0001625	98.20	gold quality
bone marrow cell	CL:0002092	98.16	gold quality
upper lobe of left lung	UBERON:0008952	97.99	gold quality
left coronary artery	UBERON:0001626	97.85	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.83	gold quality
blood	UBERON:0000178	97.78	gold quality
lymph node	UBERON:0000029	97.71	gold quality
upper lobe of lung	UBERON:0008948	97.49	gold quality
left uterine tube	UBERON:0001303	97.40	gold quality
coronary artery	UBERON:0001621	97.35	gold quality
tibial nerve	UBERON:0001323	97.15	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.13	gold quality
gall bladder	UBERON:0002110	96.97	gold quality
body of uterus	UBERON:0009853	96.84	gold quality
aorta	UBERON:0000947	96.81	gold quality
islet of Langerhans	UBERON:0000006	96.63	gold quality

Single-cell (SCXA)

Detected in 38 experiment(s), a significant marker in 28.

Experiment	Marker?	Max mean expression
E-CURD-122	yes	1806.65
E-MTAB-8142	yes	1772.51
E-HCAD-1	yes	1271.86
E-GEOD-111727	yes	897.56
E-CURD-98	yes	799.19
E-HCAD-10	yes	612.37
E-GEOD-130473	yes	258.97
E-GEOD-81608	yes	250.82
E-HCAD-4	yes	105.90
E-MTAB-6701	yes	76.50
E-HCAD-8	yes	69.49
E-MTAB-10287	yes	67.43
E-CURD-88	yes	48.56
E-GEOD-134144	yes	39.55
E-MTAB-8410	yes	35.51

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

8 targeting FXYD5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-3614-3P	97.81	67.15	582

Literature-anchored findings (GeneRIF, showing 34)

• We report the cloning and characterization of a cancer-associated cell membrane glycoprotein recognized by mAb NCC-3G10. (PMID:11756660)
• dysadherin expression was significantly associated with the prognosis, occurrence of secondary undifferentiated carcinomas, size of the primary tumor, and metastasis to the regional lymph nodes and lungs (PMID:12970317)
• dysadherin has a role in hematogenous metastasis of gastric cancer (PMID:15102690)
• Dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC (esophageal squamous cell carcinoma). (PMID:15459499)
• Dysadherin is able to modulate actin structures, stimulate cell motility, and contribute directly to the metastatic potential of human pancreatic cancer cells. (PMID:15466191)
• dysadherin may be a valuable prognostic marker in cervical carcinoma. (PMID:15619642)
• Over expression of dysadherin is associated with cutaneous malignant melanoma (PMID:15751018)
• In testicular tumours, as in other neoplasms, dysadherin downregulates E-cadherin expression, at least in part (PMID:16333245)
• Found in trophoblasts in both normal and abnormal pregnancies. (PMID:17084448)
• Dysadherin may play an important role in breast cancer progression by promoting invasion. (PMID:17437014)
• Recent work that has provided insights into possible mechanisms of action of dysadherin in the cancer progression process was reviewed. (PMID:17442482)
• FXYD5 is upregulated in cystic fibrosis epithelia which may exacerbate the Na(+) hyperabsorption and surface liquid dehydration observed in cystic fibrosis. (PMID:18263667)
• Increased dysadherin expression is possibly one of the post-transcriptional mechanisms responsible for E-cadherin downregulation in thyroid papillary neoplasia (PMID:18677652)
• The dysadherin expression level was significantly correlated with gastrointestinal stromal tumor risk stratification. (PMID:19217217)
• In lung carcinomas dysadherin expression seems to reflect tumour aggressiveness and may be considered a positive marker of poor prognosis when considered alone or/and in combination with down-regulation of E-cadherin. (PMID:20712010)
• The detection of dysadherin in tumors and cytokeratin in the lymph nodes may be a potential significant indicator of a poor prognosis for patients who undergo complete resection of stage I non-small cell lung cancer (PMID:20944097)
• transfection of dysadherin cDNA into the liver cancer cell line PLC/PRF/5 enhanced the properties of cencer stem cells, including anti-apoptosis, their sphere-forming ability, side population phenotype, and tumor initiation ability in vivo (PMID:20952084)
• Combined dysadherin-positive expression and E-cadherin-negative expression may be valuable information for predicting aggressive tumor behavior of differentiated-type gastric carcinoma with submucosal invasion (PMID:21239043)
• Data show that osteoblasts are the major cell type of the bone marrow that affect RCC cells by secreting factors that increase the expression of dysadherin and CCL2 in the tumor cells leading to enhanced cell migration. (PMID:21328336)
• This is the first report on expression of dysadherin in the male gonad and in spermatozoa. (PMID:21774927)
• Overexpression of Snail, Slug, and dysadherin and activation of Wnt and PI3K/Akt signaling was associated with inactivated E-cadherin in the spindle cells of monophasic fibrous synovial sarcomas. (PMID:21809991)
• we are focusing on the role of dysadherin in E-cadherin downregulation, the various expression patterns of the molecule in head and neck cancer (PMID:22105147)
• Findings suggest that dysadherin might contribute to breast cancer progression through AKT activation. (PMID:22494103)
• These results suggest a role of let-7a down-regulation in the development of thyroid neoplasias of the follicular histotype, likely regulating dysadherin protein expression levels. (PMID:22965940)
• Study demonstrated that the expression of FXYD1, FXYD3 and FXYD5 is elevated in the lungs of Acute respiratory distress syndrome patients (PMID:26410457)
• Dysadherin-silenced side population cells exhibited reduced expression of Bcl-2 and Bax compared with that prior to silencing. (PMID:26458963)
• Knockdown of FXYD5 in MDA-MB-231 breast cancer cells largely decreases expression and secretion of the chemokine CCL2 (MCP-1). A related effect has also been observed in renal cell carcinoma cells. (PMID:27006401)
• the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion. (PMID:27142834)
• our study demonstrated that FXYD5 is an HGSOC-associated molecule, especially overexpressed in cases characterised by shorter survival, chemotherapy resistance and disease recurrence/progression, so it might be useful for identification of patients at higher risk of worse prognosis at the time of diagnosis. (PMID:31434988)
• A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. (PMID:31746425)
• Dysadherin awakens mechanical forces and promotes colorectal cancer progression. (PMID:35673579)
• FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. (PMID:35977595)
• High-Intensity Training Represses FXYD5 and Glycosylates Na,K-ATPase in Type II Muscle Fibres, Which Are Linked with Improved Muscle K[+] Handling and Performance. (PMID:36982661)
• The dysadherin/FAK axis promotes individual cell migration in colon cancer. (PMID:38725858)

Cross-species orthologs

0 orthologs

Paralogs (6): FXYD3 (ENSG00000089356), FXYD6 (ENSG00000137726), FXYD2 (ENSG00000137731), FXYD4 (ENSG00000150201), FXYD7 (ENSG00000221946), FXYD1 (ENSG00000266964)

Protein

Protein identifiers

FXYD domain-containing ion transport regulator 5 — Q96DB9 (reviewed: Q96DB9)

Alternative names: Dysadherin

All UniProt accessions (5): Q96DB9, A8MVG1, F5H4X8, K7EJH6, K7ER99

UniProt curated annotations — full annotation on UniProt →

Function. Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. May increase NKA activity by increasing the apparent affinity for Na(+). Involved in down-regulation of E-cadherin which results in reduced cell adhesion. Promotes metastasis.

Subunit / interactions. Regulatory subunit of the sodium/potassium-transporting ATPase which is composed of a catalytic alpha subunit, a non-catalytic beta subunit and an additional regulatory subunit. The regulatory subunit, a member of the FXYD protein family, modulates the enzymatic activity in a tissue- and isoform-specific way by changing affinities of the Na+/K+-ATPase toward Na(+), K(+) or ATP.

Subcellular location. Cell membrane. Basolateral cell membrane.

Post-translational modifications. Glycosylated.

Similarity. Belongs to the FXYD family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96DB9-1	1	yes
Q96DB9-2	2

RefSeq proteins (5): NP_001158077, NP_001307841, NP_001307842, NP_054883, NP_659003 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000272	Ion-transport_regulator_FXYD	Family
IPR047297	FXYD_motif	Conserved_site

Pfam: PF02038

UniProt features (13 total): compositionally biased region 3, sequence variant 2, topological domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9KCI	ELECTRON MICROSCOPY	2.9
9KCG	ELECTRON MICROSCOPY	3.1
9KCJ	ELECTRON MICROSCOPY	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DB9-F1	58.67	0.08

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 303 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_TRANSMEMBRANE_ELECTROCHEMICAL_GRADIENT, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_CELL_CELL_ADHESION, GOBP_POTASSIUM_ION_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_SODIUM_ION_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_SODIUM_ION_TRANSPORT, GOBP_CALCIUM_DEPENDENT_CELL_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, ONKEN_UVEAL_MELANOMA_UP, GOBP_POSITIVE_REGULATION_OF_MONOATOMIC_ION_TRANSPORT, GOBP_INTRACELLULAR_POTASSIUM_ION_HOMEOSTASIS, MORI_SMALL_PRE_BII_LYMPHOCYTE_DN

GO Biological Process (7): potassium ion transport (GO:0006813), sodium ion transport (GO:0006814), microvillus assembly (GO:0030033), negative regulation of calcium-dependent cell-cell adhesion (GO:0046588), positive regulation of sodium ion export across plasma membrane (GO:1903278), monoatomic ion transport (GO:0006811), regulation of monoatomic ion transport (GO:0043269)

GO Molecular Function (5): actin binding (GO:0003779), sodium channel regulator activity (GO:0017080), cadherin binding (GO:0045296), protein binding (GO:0005515), ion channel regulator activity (GO:0099106)

GO Cellular Component (3): plasma membrane (GO:0005886), membrane (GO:0016020), basolateral plasma membrane (GO:0016323)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion transport	2
microvillus organization	1
plasma membrane bounded cell projection assembly	1
calcium-dependent cell-cell adhesion	1
negative regulation of cell-cell adhesion	1
regulation of calcium-dependent cell-cell adhesion	1
sodium ion export across plasma membrane	1
positive regulation of sodium ion transmembrane transport	1
regulation of sodium ion export across plasma membrane	1
transport	1
monoatomic ion transport	1
regulation of transport	1
cytoskeletal protein binding	1
sodium channel activity	1
ion channel regulator activity	1
cell adhesion molecule binding	1
binding	1
monoatomic ion channel activity	1
channel regulator activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1
basal plasma membrane	1
plasma membrane region	1

Protein interactions and networks

STRING

534 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FXYD5	FXYD3	Q14802	738
FXYD5	FXYD6	Q9H0Q3	729
FXYD5	COX7A1	P24310	722
FXYD5	FXYD4	P59646	720
FXYD5	A0A087WZ82	A0A087WZ82	707
FXYD5	FXYD1	O00168	689
FXYD5	FXYD7	P58549	681
FXYD5	FXYD2	P54710	674
FXYD5	CDH1	P12830	626
FXYD5	CTCFL	Q8NI51	550
FXYD5	MGAT3	Q09327	514
FXYD5	C5orf15	Q8NC54	503
FXYD5	CSDC2	Q9Y534	497
FXYD5	MRPL23	Q16540	497
FXYD5	CHD8	Q9HCK8	470

IntAct

3 interactions, top by confidence:

A	B	Type	Score
FXYD5	sepZ	psi-mi:“MI:0915”(physical association)	0.370
SLC44A1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): FXYD5 (Two-hybrid), FXYD5 (Affinity Capture-MS), FXYD5 (Affinity Capture-RNA)

ESM2 similar proteins: A0A2R8Y7Y5, A1KXC4, A6QLF8, J3KML8, O00592, O35188, O55145, O57604, P06484, P07141, P13838, P14220, P15702, P16150, P18827, P20934, P26260, P34740, P47951, P59647, P78423, P97808, Q08DZ5, Q1ECS6, Q28270, Q28645, Q29RT9, Q3MIW9, Q3TNW5, Q52S86, Q58Y74, Q5RAF8, Q62170, Q64314, Q6MG22, Q6P9X9, Q6UWI2, Q6UXF1, Q86YL7, Q8BHE4

Diamond homologs: G1TZA0, I3LMB3, O00168, O08589, O13001, O97797, P54710, P56513, P58549, P58550, P59645, P59646, P59647, P59648, P59649, Q04645, Q04646, Q04679, Q04680, Q14802, Q3MHZ5, Q3SZX0, Q3ZBJ3, Q4R566, Q5RB29, Q61835, Q63113, Q91XV6, Q96DB9, Q9D164, Q9D2W0, Q9H0Q3, Q9Z239, W5P3P0, P97808, C0HJJ0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1131 predictions. Top by Δscore:

Variant	Effect	Δscore
19:35154810:G:GG	donor_gain	1.0000
19:35157415:CCCCA:C	acceptor_loss	1.0000
19:35157416:CCCA:C	acceptor_loss	1.0000
19:35157417:CCAGG:C	acceptor_loss	1.0000
19:35157418:CA:C	acceptor_loss	1.0000
19:35157419:A:AC	acceptor_loss	1.0000
19:35157419:A:AG	acceptor_gain	1.0000
19:35157419:AG:A	acceptor_gain	1.0000
19:35157420:G:GA	acceptor_gain	1.0000
19:35157420:GG:G	acceptor_gain	1.0000
19:35157420:GGAC:G	acceptor_gain	1.0000
19:35157420:GGACA:G	acceptor_gain	1.0000
19:35158318:C:CA	acceptor_gain	1.0000
19:35158320:T:TA	acceptor_gain	1.0000
19:35164114:AT:A	acceptor_gain	1.0000
19:35164115:T:G	acceptor_gain	1.0000
19:35164115:T:TA	acceptor_gain	1.0000
19:35164116:G:A	acceptor_gain	1.0000
19:35166249:A:AG	acceptor_gain	1.0000
19:35166250:G:GG	acceptor_gain	1.0000
19:35166326:G:GG	donor_gain	1.0000
19:35169564:A:AC	acceptor_loss	1.0000
19:35169564:AGGT:A	acceptor_gain	1.0000
19:35169565:GGTG:G	acceptor_gain	1.0000
19:35154807:GAC:G	donor_gain	0.9900
19:35155550:GAT:G	acceptor_gain	0.9900
19:35155609:GAG:G	donor_gain	0.9900
19:35155611:GGTAA:G	donor_loss	0.9900
19:35155612:G:T	donor_loss	0.9900
19:35155613:T:A	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000045944 (19:35156782 G>A), RS1000117363 (19:35158119 C>A,T), RS1000441101 (19:35169089 T>C,G), RS1000628249 (19:35167389 CACTT>C), RS1000812025 (19:35168811 C>T), RS1001133382 (19:35161329 C>G), RS1001407966 (19:35155438 G>A,T), RS1001437115 (19:35167656 T>C), RS1001490577 (19:35161322 G>A), RS1001648814 (19:35155292 C>T), RS1001734726 (19:35155273 G>A), RS1001796412 (19:35159763 G>A,C), RS1001827423 (19:35159977 C>T), RS1002062648 (19:35154390 G>A), RS1002257750 (19:35160942 T>C)

Disease associations

OMIM: gene MIM:606669 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004599_149	Mean platelet volume	1.000000e-14
GCST004603_272	Platelet count	3.000000e-10
GCST004616_44	Platelet distribution width	2.000000e-21
GCST90002395_409	Mean platelet volume	4.000000e-26
GCST90002401_263	Platelet distribution width	1.000000e-46
GCST90002402_559	Platelet count	1.000000e-10

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases abundance, increases expression	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
entinostat	increases expression, affects cotreatment	2
Cadmium	decreases expression, increases abundance, increases expression	2
Nickel	increases expression	2
Cyclosporine	increases expression	2
methyleugenol	increases expression	1
bisphenol A	affects cotreatment, decreases expression	1
beta-lapachone	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	increases expression	1
Sevoflurane	increases expression	1
Rosiglitazone	increases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Troglitazone	increases expression	1
Acetaminophen	increases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases expression	1
Carbamazepine	affects expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2XE	Abcam HEK293T FXYD5 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.